New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Learn More
Last Close
Sep 16  •  04:00PM ET
2.09
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-1.43 Insider Own54.64% Shs Outstand50.13M Perf Week-0.48%
Market Cap104.79M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float22.74M Perf Month0.48%
Enterprise Value-31.22M PEG- EPS next Q- Inst Own33.91% Short Float1.56% Perf Quarter12.37%
Income-71.10M P/S- EPS this Y- Inst Trans-11.07% Short Ratio0.50 Perf Half Y18.08%
Sales0.00M P/B0.71 EPS next Y- ROA-31.47% Short Interest0.35M Perf YTD0.97%
Book/sh2.95 P/C0.66 EPS next 5Y- ROE-40.31% 52W High2.17 -3.69% Perf Year20.81%
Cash/sh3.18 P/FCF- EPS past 3/5Y4.05% -166.47% ROIC-42.39% 52W Low1.34 55.97% Perf 3Y-89.02%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility0.86% 1.26% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM57.64% Oper. Margin- ATR (14)0.03 Perf 10Y-
Dividend Ex-Date- Quick Ratio26.39 Sales Y/Y TTM- Profit Margin- RSI (14)51.29 Recom3.00
Dividend Gr. 3/5Y- - Current Ratio26.39 EPS Q/Q87.29% SMA200.06% Beta0.77 Target Price2.00
Payout- Debt/Eq0.16 Sales Q/Q- SMA500.02% Rel Volume0.00 Prev Close2.09
Employees14 LT Debt/Eq0.13 EarningsAug 06 AMC SMA2009.04% Avg Volume712.43K Price2.09
IPOApr 29, 2022 Option/ShortNo / No EPS/Sales Surpr.67.12% - Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Jul-09-24Downgrade Stifel Buy → Hold $34 → $3
Jul-09-24Downgrade Leerink Partners Outperform → Market Perform $28 → $2
Jul-09-24Downgrade H.C. Wainwright Buy → Neutral $28 → $2
Jul-08-24Downgrade JP Morgan Overweight → Neutral $24 → $5
Jul-08-24Downgrade Guggenheim Buy → Neutral
Dec-13-23Initiated H.C. Wainwright Buy $28
Aug-06-25 04:05PM
Aug-04-25 07:00AM
Jul-11-25 12:00PM
May-08-25 07:00AM
Mar-28-25 05:00PM
08:00AM Loading…
Nov-07-24 08:00AM
Oct-14-24 12:00PM
Aug-08-24 07:20PM
Aug-01-24 11:53AM
Jul-31-24 04:00PM
Jul-29-24 09:35AM
Jul-11-24 09:35AM
Jul-09-24 10:19AM
Jul-08-24 12:36PM
12:17PM
08:42AM Loading…
08:42AM
08:16AM
07:30AM
May-23-24 02:15AM
May-10-24 02:26PM
May-09-24 11:55PM
04:05PM
Apr-14-24 12:52PM
Apr-06-24 01:33AM
Mar-21-24 02:32AM
Mar-20-24 09:53PM
04:00PM
Mar-08-24 11:55PM
Feb-22-24 11:27PM
Feb-05-24 04:05PM
07:00AM Loading…
Jan-18-24 07:00AM
Jan-08-24 07:00AM
Jan-03-24 06:28PM
Dec-19-23 01:01PM
Dec-05-23 09:48PM
Nov-30-23 09:55AM
Nov-21-23 11:03AM
Nov-14-23 12:00PM
09:55AM
Nov-09-23 04:05PM
Nov-01-23 04:48PM
Sep-26-23 04:01PM
Sep-25-23 07:00AM
Sep-19-23 08:05PM
04:09PM
Aug-24-23 10:40AM
Aug-14-23 05:08PM
07:00AM
Jun-07-23 09:55AM
May-22-23 09:55AM
May-12-23 04:05PM
May-09-23 07:00AM
Apr-25-23 06:45AM
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HERSHBERG ROBERTSee RemarksFeb 04 '25Sale1.8914,63427,6581,113,399Feb 12 04:05 PM
HERSHBERG ROBERTSee RemarksFeb 11 '25Sale1.7611,90121,0031,101,498Feb 12 04:05 PM
Maltbie ShaneChief Financial OfficerFeb 11 '25Sale1.764,3457,65979,887Feb 12 04:05 PM
Maltbie ShaneChief Financial OfficerFeb 04 '25Sale1.893,9467,45884,232Feb 12 04:05 PM